BR112016029749A2 - composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições - Google Patents
composições que compreendem cinamaldeído e zinco e métodos de uso de tais composiçõesInfo
- Publication number
- BR112016029749A2 BR112016029749A2 BR112016029749A BR112016029749A BR112016029749A2 BR 112016029749 A2 BR112016029749 A2 BR 112016029749A2 BR 112016029749 A BR112016029749 A BR 112016029749A BR 112016029749 A BR112016029749 A BR 112016029749A BR 112016029749 A2 BR112016029749 A2 BR 112016029749A2
- Authority
- BR
- Brazil
- Prior art keywords
- cinnamaldehyde
- composition
- zinc
- compositions
- overweight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 title abstract 7
- 229940117916 cinnamic aldehyde Drugs 0.000 title abstract 7
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 title abstract 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000011701 zinc Substances 0.000 title abstract 4
- 229910052725 zinc Inorganic materials 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000003931 cognitive performance Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000015654 memory Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 210000002820 sympathetic nervous system Anatomy 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 230000037221 weight management Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
a presente invenção refere-se a composições que compreendem uma quantidade de cinamaldeído que é tolerável para ingestão oral, evitando assim uma sensação desagradável na boca, e que é também tolerável no trato gastrointestinal. a quantidade de cinamaldeído é suplementada por zinco, e a combinação é eficaz para aumentar ao menos um dentre gasto energético, atividade do sistema nervoso simpático, ou oxidação de gordura, em relação a uma composição isenta de cinamaldeído e zinco mas, de outro modo, idêntica. a composição compreendendo a combinação de cinamaldeído e zinco pode ser usada em um método para ajudar no gerenciamento de peso ou para promover a perda de peso, em um método para evitar obesidade ou excesso de peso, e em um método para tratar obesidade ou excesso de peso. em uma modalidade, a composição compreendendo cinamaldeído é administrada a um ser humano. a composição compreendendo cinamaldeído pode ser um medicamento, um produto alimentício ou um suplemento. a composição pode melhorar um ou mais dentre sensibilidade à insulina, tolerância à glicose, desempenho cognitivo, cognição, humor ou memória.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462026157P | 2014-07-18 | 2014-07-18 | |
| US62/026,157 | 2014-07-18 | ||
| PCT/EP2015/062696 WO2016008642A2 (en) | 2014-07-18 | 2015-06-08 | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016029749A2 true BR112016029749A2 (pt) | 2017-08-22 |
| BR112016029749A8 BR112016029749A8 (pt) | 2021-03-16 |
| BR112016029749B1 BR112016029749B1 (pt) | 2021-10-26 |
Family
ID=53366030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016029749-0A BR112016029749B1 (pt) | 2014-07-18 | 2015-06-08 | Uso de cinamaldeído e de composto compreendendo zinco na preparação de composições alimentícias |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10092028B2 (pt) |
| EP (2) | EP3169170B1 (pt) |
| JP (2) | JP2017526643A (pt) |
| CN (1) | CN106470691B (pt) |
| AU (1) | AU2015291442B2 (pt) |
| BR (1) | BR112016029749B1 (pt) |
| CA (2) | CA2951090A1 (pt) |
| ES (1) | ES2822524T3 (pt) |
| WO (1) | WO2016008642A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672798T5 (es) * | 2014-03-20 | 2021-07-14 | Nestle Sa | Composición que comprende cinamaldehído y zinc, para mejorar la deglución |
| ES2743955T3 (es) * | 2015-06-05 | 2020-02-21 | Nestle Sa | Composiciones que comprenden cinamaldehído y zinc y métodos para utilizar tales composiciones |
| WO2018129095A1 (en) * | 2017-01-03 | 2018-07-12 | Thermolife International, Llc | Cinnamaldehyde compositions and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469674A (en) * | 1981-09-03 | 1984-09-04 | Richardson-Vicks Inc. | Stable oral compositions containing zinc and fluoride compounds |
| WO2001028503A1 (en) * | 1999-10-19 | 2001-04-26 | The Nutrasweet Company | PERSONAL CARE PRODUCTS USING N-[N-(3,3-DIMETHYLBUTYL)-1-α-ASPARTYL]-L-PHENYLALANINE METHYL ESTER |
| DE202004017113U1 (de) * | 2004-11-05 | 2004-12-30 | Salus-Haus Gmbh & Co. Kg | Momordica charantia-Zimt-Zubereitung |
| KR20120122597A (ko) * | 2011-04-29 | 2012-11-07 | 영남대학교 산학협력단 | 계피 추출물을 유효성분으로 함유하는 대사증후군의 예방 및 치료용 조성물 |
| US20160339058A1 (en) * | 2014-03-20 | 2016-11-24 | Nestec S.A. | Methods and compositions for using cinnamaldehyde and zinc for weight management |
-
2015
- 2015-06-08 EP EP15727655.1A patent/EP3169170B1/en active Active
- 2015-06-08 CN CN201580034856.3A patent/CN106470691B/zh active Active
- 2015-06-08 CA CA2951090A patent/CA2951090A1/en active Pending
- 2015-06-08 EP EP20184577.3A patent/EP3756475A1/en active Pending
- 2015-06-08 BR BR112016029749-0A patent/BR112016029749B1/pt active IP Right Grant
- 2015-06-08 JP JP2017501660A patent/JP2017526643A/ja active Pending
- 2015-06-08 AU AU2015291442A patent/AU2015291442B2/en active Active
- 2015-06-08 CA CA3132696A patent/CA3132696C/en active Active
- 2015-06-08 ES ES15727655T patent/ES2822524T3/es active Active
- 2015-06-08 US US15/327,108 patent/US10092028B2/en active Active
- 2015-06-08 WO PCT/EP2015/062696 patent/WO2016008642A2/en active Application Filing
-
2019
- 2019-04-25 JP JP2019084115A patent/JP6869286B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2951090A1 (en) | 2016-01-21 |
| EP3169170A2 (en) | 2017-05-24 |
| BR112016029749B1 (pt) | 2021-10-26 |
| US20170164648A1 (en) | 2017-06-15 |
| ES2822524T3 (es) | 2021-05-04 |
| CA3132696C (en) | 2023-10-10 |
| CN106470691A (zh) | 2017-03-01 |
| EP3756475A1 (en) | 2020-12-30 |
| WO2016008642A3 (en) | 2016-03-17 |
| JP2019142940A (ja) | 2019-08-29 |
| CA3132696A1 (en) | 2016-01-21 |
| AU2015291442B2 (en) | 2019-04-11 |
| BR112016029749A8 (pt) | 2021-03-16 |
| CN106470691B (zh) | 2020-04-03 |
| US10092028B2 (en) | 2018-10-09 |
| JP6869286B2 (ja) | 2021-05-12 |
| EP3169170B1 (en) | 2020-07-08 |
| JP2017526643A (ja) | 2017-09-14 |
| AU2015291442A1 (en) | 2016-12-08 |
| WO2016008642A2 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014021388A2 (pt) | composições de microbiota e métodos rela-cionados às mesmas | |
| BR112013010021A2 (pt) | combinações farmacêuticas para o tratamento de distúrbios metabólicos. | |
| BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
| BR112013010556A2 (pt) | métodos e composições adequadas para a promoção de uma pele saudável | |
| EP3318262A3 (en) | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease | |
| BR112014020188A8 (pt) | Dispositivo médico para uso com um material de enchimento para ocupar temporariamente um espaço dentro de um corpo do paciente para tratar obesidade | |
| BR112012022801B8 (pt) | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer | |
| CO2018002394A2 (es) | Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| BR112017006416A2 (pt) | composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico | |
| BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
| BR112015017251A8 (pt) | composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas | |
| BR112012005044B8 (pt) | composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib | |
| MX2016009231A (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| BR112013026661A2 (pt) | método de entrega de vacina | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| EP3318251A3 (en) | Composition for preventing or treating obesity or lipid-related metabolic disease | |
| BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
| BR112014027738A2 (pt) | ácido graxo de talóleo que é modificado por saponificação para uso, suplemento alimentar, e composto alimentar | |
| BR112016029749A2 (pt) | composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições | |
| HRP20230070T1 (hr) | Tasimelteon za liječenje smith-magenis sindroma | |
| BR112019010057A2 (pt) | composição, método para suprimir a ingestão de comida, sequência de shrna, método de inibição da síntese de ácidos graxos | |
| BR112016025481A2 (pt) | alimentos, sistemas, métodos e estojos para provisão de substituição de eletrólito | |
| BR112017026834A2 (pt) | composição compreendendo vitaminas b e vitaminas c e seu uso | |
| BR112015017903A2 (pt) | vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2015, OBSERVADAS AS CONDICOES LEGAIS. |